Related references
Note: Only part of the references are listed.Effect of Knowledge of APOE Genotype on Subjective and Objective Memory Performance in Healthy Older Adults
Tara T. Lineweaver et al.
AMERICAN JOURNAL OF PSYCHIATRY (2014)
The A4 Study: Stopping AD Before Symptoms Begin?
Reisa A. Sperling et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
Keith A. Johnson et al.
ALZHEIMERS & DEMENTIA (2013)
Disclosure of amyloid imaging results to research participants: Has the time come?
Jennifer H. Lingler et al.
ALZHEIMERS & DEMENTIA (2013)
Testing the use of standardized scripts for disclosing ‘hypothetical/mock’ amyloid PET scan results to nondemented cognitively impaired patients and their care partners
Michael Witte et al.
Alzheimers & Dementia (2013)
The psychological impact of genetic risk information on individuals with mild cognitive impairment at imminent risk for conversion to Alzheimer's disease dementia: Findings from the REVEAL Study
Kurt Christensen et al.
Alzheimers & Dementia (2013)
Disclosing amyloid imaging results in MCI: What do patients and families want, and why?
Jennifer Lingler et al.
Alzheimers & Dementia (2013)
OPINION Preclinical Alzheimer disease-the challenges ahead
Reisa A. Sperling et al.
NATURE REVIEWS NEUROLOGY (2013)
Using AD biomarker research results for clinical care A survey of ADNI investigators
Melanie B. Shulman et al.
NEUROLOGY (2013)
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease
Gael Chetelat et al.
NEUROIMAGE-CLINICAL (2013)
Should we disclose amyloid imaging results to cognitively normal individuals?
Joshua D. Grill et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2013)
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues
J. Scott Roberts et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2013)
Development of a standardized approach to disclosing amyloid imaging results in MCI
Jennifer Lingler et al.
Alzheimers & Dementia (2012)
Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease
J. Scott Roberts et al.
GENETICS IN MEDICINE (2012)
Predicting positivity for a new era of Alzheimer disease prevention trials
Jeffrey M. Burns et al.
NEUROLOGY (2012)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics
J. S. Roberts et al.
CLINICAL GENETICS (2011)
Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease
Jason Karlawish
NEUROLOGY (2011)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack et al.
LANCET NEUROLOGY (2010)
Where there is no evidence: use of expert consensus methods to fill the evidence gap in low-income countries and cultural minorities
Harry Minas et al.
INTERNATIONAL JOURNAL OF MENTAL HEALTH SYSTEMS (2010)
Disclosure of APOE Genotype for Risk of Alzheimer's Disease
Robert C. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Delphi method as a research tool: an example, design considerations and applications
C Okoli et al.
INFORMATION & MANAGEMENT (2004)
Share Paper
